Abstract: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.

Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Abstract: The present disclosure relates to compositions and methods of increasing magnesium bioavailability and absorption.

Abstract: Storage stable aqueous ready-to-administer formulations comprising isoproterenol are presented with desirable stability characteristics. In preferred aspects, formulations are terminally sterilized and packaged in a suitable format, such as a polymeric bag with metalized overwrap and include a non-contact oxygen scavenger.

Abstract: An anxiolytic composition includes a synergistic combination of one or more of an L-theanine, an s-adenosylmethionine (SAMe), and optionally an extract of Magnolia, an extract of Phellodendron, and a whey protein.

Abstract: Disclosed is a method of manufacturing a cardiovascular fixed-dose combination pharmaceutical dosage form that includes an anti-hypertensive active agent, a cholesterol-lowering active agent, and optionally, an enteric-coated aspirin or platelet inhibitor. The fixed-dose combination is prepared with at least two granulation solutions that are free of citric acid and enhance the aqueous solubility of the cholesterol-lowering agent in fixed-dose combination. The active agents in the resulting dosage form, which is also free of citric acid, have the same strength and release profiles as the same active agents prepared as a single formulation.

Abstract: The present invention relates to the use of scaffolds to enhance the viability of cells implanted in the integumentary system such that the cell may release an agent. The scaffold is capable of protecting the cell, as well as allowing for adequate nutrient delivery at the implant site through vascularisation in and around the scaffold.

Abstract: Provided are co-crystals of a sodium benzoate compound and a co-former compound of Formula (I) Also provided herein are methods of preparing the co-crystals and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease) or a glucose or lipid metabolic disorder (e.g., obesity, diabetes, hypercholesterolemia, hypertension, or hyperlipidemia).

Abstract: The invention provides methods for preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s) in a subject comprising administering an aldehyde sequestering agent so as to reduce or counter blood aldehyde buildup in the subject, thereby preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s) in the subject.

Abstract: The invention relates to a food supplement containing minerals and/or vitamins, a humectant and, for example, essential oils. The food supplement is formulated as an oral spray. In particular, the invention relates to a concentrated food supplement in the form of an oral spray, containing a combination of magnesium ions, panthenol (vitamin B5), caffeine, menthol aroma and/or peppermint aroma, and a humectant. The food supplement is particularly suited for use in sport and in stressful situations.

Abstract: Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.

Abstract: Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.

Abstract: The present invention relates to use of peptides as a therapeutic agent, wherein it has been confirmed that the peptides of the present invention significantly inhibit the activity of T cells and the differentiation of T helper 17 cells (Th17 cells), which are associated with autoimmune disease, and have remarkable effects of treating and improving arthritis in an animal model of arthritis. Therefore, the peptides may be used as an active ingredient in therapeutic agents for various autoimmune diseases such as bone disease, inflammatory disease or rheumatoid arthritis.

Abstract: The invention concerns a composition, advantageously cosmetic, comprising: at least one basic amino acid selected from the group constituted by arginine, lysine, histidine, ornithine, hydroxyproline and one of their salts; and at least one glycosylceramide, and its use for preventing and/or treating atopic dermatitis.

Abstract: A method of treating coronavirus infection, post-acute sequelae of coronavirus infection, and viral mediated respiratory distress in a subject in need thereof includes administering to the subject a therapeutically effective amount of agent that promotes, increases, and/or induces hemoglobin nitrosylation within red blood cells (RBCs) and GSNO levels in the lung or airways of the subject.

Abstract: An organic UVA filter-stabilized antioxidant system demonstrates stabilization after UV exposure as compared with controls lacking the UVA filter stabilizer. The organic UVA filter-stabilized antioxidant system provides a cosmetic composition that confers preserved and sustained antioxidant efficacy to keratinous tissue. The antioxidant system includes a combination of at least one hydroxycinnamate derivative, and an organic, water-soluble UVA filter in a water-based carrier.

Abstract: The invention concerns a device and a method for the preparation of a liquid composition for oral administration of a liquid composition formed by a liquid component and a component in powder form, for the treatment of persons affected by metabolic disorders, in particular appropriately selecting the compounds to be added to the drink according to the specific metabolic disorder.

Abstract: The micronutrient and plant extract composition comprises of a vitamin C, vitamin A (?-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methylsulfonylmethane (MSM) and stinging nettle extract and in combination it is used for treating, and reversing bone demineralization. The micronutrient and plant extract composition when administered to mammal with or without bone disease strengthens and helps in bone mineralization process. The composition can be used as a preventive dose for bone demineralization in human.

Abstract: A process for the production of a solid cosmetic preparation is described wherein a wax phase comprising at least one wax, at least one oil, and if applicable, oil-soluble ingredients and solvents are melted, the molten wax phase is mixed with an aqueous phase comprising at least one water-soluble or water-soluble water-dispersible film former and with a w/o emulsifying system until an emulsion is formed, and the resulting emulsion is allowed to cool to form a wax matrix with aqueous phase droplets embedded therein, and the products made therefrom and their use.

Abstract: A device and protective composition is described that is used in the context of first aid for skin contact with acids, bases, oxidizing agents, formaldehyde and fluorides serving to neutralize and inactivate the chemicals. The device comprises a two-chamber applicator that contains a first preparation in a first chamber, such as an antioxidant, and a second preparation in a second chamber, such as a solution that contains a buffer and a calcium salt. The two preparations are mixed just before application and are applied to the affected areas by the device.

Abstract: Compositions and methods are disclosed for treating anxiety or stress in an animal, for reducing elevated levels of 4-EPS in an animal with elevated 4-EPS levels, for preventing elevated levels of 4-EPS in an animal and for promoting growth of beneficial microbes in an animal's microbiome and inhibiting growth of non-beneficial microbes. The methods comprise administering to the animal an effective amount of soy protein and vitamin C. Compositions are disclosed which comprise amounts of soy protein and vitamin C effective for use in the methods.

Abstract: The invention relates to a cosmetic composition comprising one or more pyridinedicarboxylic acid derivatives of general formula (I) or a salt thereof and one or more antioxidants chosen from flavone heterosides, polyhydroxylated stilbenes, pyrimidinecarboxylic acid derivatives and ascorbic acid esters.

Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effect amount of a first cleansing solution; and then after a time interval—administering to the subject an effective amount of a second cleansing solution, wherein the two cleansing solutions are as described in the specification.

Abstract: Example embodiments of the present invention include various compositions that include a pH modifier composition and/or a buffering capacity modifier composition. In some examples, the pH modifier compositions include a dose of pH modifier to raise the pH in a patient's mouth from about 1 to about 2 pH levels. The compositions are then incorporated into various confections for oral ingestion or application that allow a patient to easily use the composition with the pH and/or buffering capacity modifiers. For example, compositions with the pH and/or buffering capacity modifiers can be incorporated within chewing gum, tablets, lozenges, breath strips, hard candy, oral sprays, and other confections. Another embodiment of the invention includes a testing device to test the pH and buffering capacity within a patient's mouth.

Abstract: Disclosed is a method for preparing high-quality anhydrous choline halide single crystal and its derivatives. The single crystal product has good stability of light and heat. It also has the advantages of moisture resistant, deliquescent resistance and is not easy to agglomerate. The method is simple in operation. The solvent used in the process is difficult to volatilize and can be recycled.

Abstract: The agent with antistress, anxiolytic and antidepressant activity and a composition based on it. The invention relates to the field of pharmaceutics, particularly to chemical compounds based on lithium salts, namely to substances with antistress, anxiolytic and antidepressant activity and can be used in medicine, veterinary medicine, and the pharmaceutical industry. The invention discovers the possibility of using lithium ascorbate as an agent with antistress, anxiolytic and antidepressant activity. The claimed composition with antistress, anxiolytic and antidepressant activity, including a lithium salt, contains pyridoxine hydrochloride, thiamine mononitrate and lithium ascorbate as a lithium salt. The use of lithium ascorbate as an agent with antistress, anxiolytic and antidepressant action and the composition based on it, enables to expand the assortment of the agents for indicated administration. At the same time, the claimed agents have low toxicity and high efficacy.

Abstract: The present invention provides a cosmetic composition containing (A) 3-O-alkyl-L-ascorbic acid wherein the alkyl group has 8-12 carbon atoms or a salt thereof, (B) one or more kinds of nonionic surfactants selected from the group consisting of polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkyl ether and polyoxyethylene alkenyl ether, and having an HLB value of 12.5-17, and (C) one or more kinds of oil agents selected from the group consisting of amino acid ester, dimer acid ester, hydroxy acid ester, alkyl glyceryl ether and alkenyl glyceryl ether, which is superior in solubilization stability, preservation stability and sense of use, and free of time-dependent development of an odor which poses a problem when in use.

Abstract: The present invention provides a novel radiosensitizer or anti-cancer chemotherapy sensitizer. In particular, the invention provides a radiosensitizer or anti-cancer chemotherapy sensitizer that can relieve the irritation of an affected area caused by hydrogen peroxide, is safe when injected into a human body, and can delay or reduce the degradation of hydrogen peroxide and thereby can efficiently exert a radiation sensitizing effect and an anti-cancer chemotherapy sensitizing effect. The radiosensitizer or anti-cancer chemotherapy sensitizer comprises a combination of (a) hydrogen peroxide and (b) hyaluronic acid or salt thereof.

Abstract: The object of the present invention is a pharmaceutical formulation of racecadotril characterized by high bioavailability. In particular, the present invention relates to a method of dry granulating racecadotril in the presence of a hydrophilic excipient and a disintegrant, preferably with a low moisture content; said method being carried out by means of a tablet machine or alternately a roller compacting machine, carrying out the compaction step with a compaction strength of less than 30 kN and equal to or greater than 4 kN, and the step of grinding the slugs and screening so as to obtain a granulate in which not more than 50% by weight of the product has a particle size of less than 90 micron.

Abstract: Provided herein is an oral care composition comprising an orally-acceptable aqueous vehicle and an antimicrobial ingredient, wherein the antimicrobial ingredient comprises a zinc ascorbylphosphate and methods for treating or preventing a disease or disorder of the oral cavity using the oral care compositions disclosed herein.

Abstract: Provided herein is a pharmaceutical composition comprising vitamin C and chromium-free vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Also provided herein is a chromium-free pharmaceutical composition comprising vitamin C and vitamin K, and optionally one or more pharmaceutically acceptable excipient(s). Further provided herein is a method of treating, preventing, or managing an NF?B-mediated condition, disorder, or disease, comprising administering to the subject a therapeutically effective amount of vitamin C and chromium-free vitamin K. Provided herein are methods for treating, preventing, or ameliorating one or more symptoms of a polycystic disease in a subject, comprising administering to the subject a therapeutically effective amount of vitamins C and K.

Abstract: Embodiments herein relate to animal feed preservatives including byproducts containing levulinic acid and methods of making and using the same. In an embodiment, a method of making an animal feed preservative is included. The method can include obtaining an acidic byproduct of a manufacturing process. The acidic byproduct can include at least about 1% by weight levulinic acid or a salt thereof. The method can further include mixing the acidic byproduct with a base to form the animal feed preservative. The animal feed preservative can include at least about 5 wt. % of the acid byproduct. In various embodiments, a method of reducing the amount of mycotoxins formed in an animal feed product during storage is included. In various embodiments, an animal feed preservative or supplement is included. Other embodiments are also included herein.

Abstract: Methods for treating cancers, tumors, and neoplasms using a composition comprising one or more generally regarded as safe (GRAS) compounds selected from the group of components consisting of vitamins, selenium, fatty acids, fatty acid salts, and fatty acid esters, and mixtures of two or more said components, either as a stand-alone treatment or in combination with one or more anti-cancer drugs or devices or other anti-neoplastic agents, treatments, or devices are provided. In some instances, concomitant hyperthermia therapy is employed. Also provided are compositions and kits containing the compositions, for implement various aspects of the invention.

Abstract: The present invention provides a formulation comprising a corticosteroid and an insulin analog. Also provided is a formulation comprising a corticosteroid, an insulin analog and at least one organic acid. Further provided are pharmaceutical compositions of the formulations described herein. The present invention provides methods for stimulating bone and/or cartilage growth, for stimulating hair growth and/or reducing hair loss, for stimulating growth of a tooth and/or periodontium and for treating tumors and cysts of the jaw by administering the formulations described herein.

Abstract: An inhibitor of visceral fat loss is capable of suppressing body weight loss peculiarly found in Parkinson's disease patients. The inhibitor of visceral fat loss in Parkinson's disease patients of the present invention contains a lipid obtained by subjecting a medium-chain triglyceride that includes as a constitutive fatty acid at least one of a saturated fatty acid having 8 carbon atoms and a saturated fatty acid having 10 carbon atoms to a transesterification reaction with a vegetable oil. The lipid is preferably obtained by subjecting the medium-chain triglyceride to a transesterification reaction with the vegetable oil at a ratio of 10:90 to 20:80.

Abstract: Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

Abstract: Disclosed is use of andrographolide derivative as shown by general formula 1 in manufacture of medicaments for anti-hepatitis C virus, and preventing and treating immunological liver damage caused by virus infection and different chemical liver damage.

Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per litre ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.

Abstract: Disclosed are methods of mitigating the effects of exposure to oxidizing agents, chlorinating and/or brominating agents on biological and/or synthetic fibers, by treating the body and/or clothing fibers with an effective amount of a composition comprising compounds of formula A. Also disclosed are compositions comprising compounds of formula A, for use in treating biological and/or synthetic fibers to mitigate the effects of exposure to chlorinating and/or brominating agents.

Abstract: A complex formed of at least one molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or a derivative covalently bonded with at least one hydrocarbon radical with formula (A) as follows: wherein: •-m 1=1, 2, 3, 4, 5 or 6; •-m 2=0, 1, 2, 3, 4, 5 or 6; and represents the site of the bond with the molecule of 5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5H-furan-2-one or derivative.

Abstract: An anti-aging composition containing: (a) at least one first active ingredient chosen from phloretin and its derivatives; (b) at least one second active ingredient chosen from cinnamic acid, resveratrol, retinol, ascorbic acid, tocopherol, and their derivatives; and (c) at least one non-aqueous organic solvent, with the proviso that if the composition contains ascorbic acid, water is present as a co-solvent.

Abstract: Disclosed are waving compositions for waving of keratinous fibers, such as hair, containing a) a bisulfite compound, b) a sulfate compound or urea, and c) a lactone or about 0.3% or greater, by weight, of ascorbic acid or a derivative thereof, based on the total weight of the composition and methods of waving keratinous fibers by applying such compositions to keratinous fibers. Also disclosed is a multi-unit cosmetic kit for treating a keratinous fiber containing a) a first unit containing a first composition containing a bisulfite compound and a sulfate compound or urea, and b) a second unit containing a second composition containing a lactone or ascorbic acid or a derivative thereof.

Abstract: Provided herein is a method of treating, preventing, or managing osteolysis in a subject, comprising administering to the subject a therapeutically effective amount of vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in combination with vitamin K, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

Abstract: A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury.

Abstract: This invention is based upon the discovery that a mixture of ethyl lactate and isoamyl lactate can be used to improve the penetration of active ingredients in skin care formulations through the outer layers of the stratum corneum and viable epidermis and into the dermis layer of the skin structure. The present invention more specifically discloses a method of rejuvenating skin comprising topically applying a topical formulation to the skin, wherein the topical formulation is comprised of ascorbic acid, an amino acid selected from the group consisting of phenylalanine and tyrosine, a non-toxic zinc salt, carnosic acid, ?-tocopherol, 0.01 weight percent to 20 weight percent of a mixture of ethyl lactate and isoamyl lactate, wherein the weight ratio of the ethyl lactate to the isoamyl lactate is within the range of 1:10 to 20:1, and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to an ophthalmological vehicle system for the permeation and/or for the active substance transport of ophthalmological active substances through the cornea and/or the sclera of the eye of mammals. This vehicle system assists the transport of the active substances through the cornea and/or the sclerotic tissue of the eye. The vehicle system is suitable for the prophylaxis and/or treatment of diseases of the front and/or back portion of the eye. Likewise, the present invention relates to an ophthalmological kit, comprising a special ophthalmological composition and also, as separate formulation, an ophthalmological active substance.

Abstract: The present invention relates to solid, color-stable L-ascorbic acid compositions, which are in the form of a powder or granule. These improved compositions have a high amount of vitamin C and they have excellent color stability.

Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.

Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.

Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.